Keryx Biopharmaceuticals Inc., of Boston, reported U.S. product sales of Auryxia (ferric citrate) totaling $2.8 million in the fourth quarter, up 70 percent over the fourth quarter of 2015, despite the three-month supply interruption from August to November. Full-year sales of the hyperphosphatemia drug totaled $27.2 million, up 170 percent year over year. Total revenues were $9.5 million and $32 million for the quarter and full year, respectively. Keryx posted a fourth-quarter net loss of $33.8 million, or 32 cents per share. Consensus estimates had predicted a loss of 25 cents per share. For the full year, the net loss was $161.1 million, or $1.52 per share. The company ended the year with about $111.8 million on its balance sheet. Shares of Keryx (NASDAQ:KERX) closed Wednesday at $4.84, down 19 cents. (See BioWorld Today, Aug. 2, 2016.)